Google
ALMS — ALUMIS INC (Healthcare >> Biotechnology)
ALMS FAQ
What is ALMS's P/E ratio?
ALUMIS INC (ALMS) currently trades at a P/E ratio of 43.16.
What is ALMS's ROE?
ALUMIS INC reports a Return on Equity (ROE) of -41.87%.
What is ALMS's dividend yield?
ALUMIS INC offers a dividend yield of 0.00%.
What is ALMS's Deepscope Quality Score?
Deepscope rates ALMS's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ALMS?
Deepscope's AI Timing Score for ALMS is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ALMS belong to?
ALUMIS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 19.06
Price
-1.33
(-6.52%)
Day Change
|
|
|---|
ALMS, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 19.06 |
| PBV / Sector |
4.51 / 4.63
|
| Earning Per Share | -1.77 |
| PE / Sector |
43.16 / 17.43
|
| PEG or PE/Growth / Sector |
1.85 / 0.53
|
| Average 1M Daily Value |
19.78 M
GREAT
|
| Average 1W Daily Value |
25.24 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:08:26 |
| Symbol | ALMS |
| Name | ALUMIS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 123.43 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2,560.04 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 280 East Grand Avenue, South San Francisco, CA, United States, 94080
Phone: 650 231 6625
Website: https://www.alumis.com
Employees: 225
Sector: Healthcare >> Biotechnology
Description: Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
